The risks of miRNA therapeutics: in a drug target perspective
S Zhang, Z Cheng, Y Wang, T Han - Drug design, development …, 2021 - Taylor & Francis
RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs,
were approved by the Food and Drug Administration in 2018 and 2019, respectively …
were approved by the Food and Drug Administration in 2018 and 2019, respectively …
Trials and tribulations of MicroRNA therapeutics
AA Seyhan - International Journal of Molecular Sciences, 2024 - mdpi.com
The discovery of the link between microRNAs (miRNAs) and a myriad of human diseases,
particularly various cancer types, has generated significant interest in exploring their …
particularly various cancer types, has generated significant interest in exploring their …
[HTML][HTML] Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry
P Wang, Y Zhou, AM Richards - Theranostics, 2021 - ncbi.nlm.nih.gov
The approval of the first small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks
a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post …
a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post …
Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine
C Chakraborty, AR Sharma, G Sharma… - … Therapy-Nucleic Acids, 2017 - cell.com
In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are
some of the most important biopharmaceuticals that are in commercial space as future …
some of the most important biopharmaceuticals that are in commercial space as future …
RNA-based therapeutics: from antisense oligonucleotides to miRNAs
S Bajan, G Hutvagner - Cells, 2020 - mdpi.com
The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was …
1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was …
Clinical applications of short non-coding RNA-based therapies in the era of precision medicine
Simple Summary RNA-based drugs are an attractive approach for personalized treatment of
cancer and other diseases. This review focuses on two related classes of short non-coding …
cancer and other diseases. This review focuses on two related classes of short non-coding …
Drug target miRNAs: chances and challenges
MF Schmidt - Trends in biotechnology, 2014 - cell.com
miRNAs, short ribonucleic acid gene regulators, are increasingly popular drug targets.
Traditionally 'undruggable'proteins can be targeted via their miRNA gene regulators …
Traditionally 'undruggable'proteins can be targeted via their miRNA gene regulators …
The race of 10 synthetic RNAi-based drugs to the pharmaceutical market
R Titze-de-Almeida, C David… - Pharmaceutical …, 2017 - Springer
Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-
stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes …
stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes …
[HTML][HTML] Therapeutic advances of miRNAs: A preclinical and clinical update
C Chakraborty, AR Sharma, G Sharma… - Journal of advanced …, 2021 - Elsevier
Background miRNAs, a class of small endogenous RNAs, are one of the essential
biopharmaceuticals which are in commercial spans as next-generation medicine in recent …
biopharmaceuticals which are in commercial spans as next-generation medicine in recent …
RNAi-based therapeutics and novel RNA bioengineering technologies
RNA interference (RNAi) provides researchers with a versatile means to modulate target
gene expression. The major forms of RNAi molecules, genome-derived microRNAs …
gene expression. The major forms of RNAi molecules, genome-derived microRNAs …